Beyondspring Inc (BYSI)

$1.71 +0.05 (2.71%)
Market Cap 70.11M
Revenue (ttm) 0.00
Net Income (ttm) -1.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,900
Avg Vol 18,606
Day's Range N/A - N/A
Shares Out 41.12M
Stochastic %K 53%
Beta 0.51
Analysts Strong Buy
Price Target $1.25

Company Profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Pl...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 305 6387
Address:
100 Campus Drive, 4th Floor, Suite 410 West Side, Florham Park, United States
SuperGreenToday
SuperGreenToday Apr. 23 at 7:05 AM
$BYSI Share Price: $1.63 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.06 – $0.08 Potential Upside: 56% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
winners3628
winners3628 Apr. 22 at 1:11 PM
$BYSI more data at asco
0 · Reply
michele1twits
michele1twits Apr. 22 at 11:34 AM
$BYSI https://ca.finance.yahoo.com/news/beyondspring-reports-compelling-data-plinabulin-110000913.html
0 · Reply
winners3628
winners3628 Apr. 10 at 12:25 PM
$BYSI https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline
0 · Reply
Goodstockday
Goodstockday Apr. 7 at 1:13 AM
$BYSI So is this a Chinese stock with an office in the US? Anyone know the history or structure?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 23 at 4:37 PM
$BYSI RSI: 56.69, MACD: 0.0538 Vol: 0.15, MA20: 1.53, MA50: 1.53 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ApolloAlerts
ApolloAlerts Mar. 20 at 3:45 PM
$BYSI 2-3$
0 · Reply
michele1twits
michele1twits Mar. 3 at 6:00 PM
$BYSI daytradersplaying silly buggers
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 4:20 PM
$BYSI RSI: 25.00, MACD: -0.1042 Vol: 0.12, MA20: 1.49, MA50: 1.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
snipethad
snipethad Feb. 17 at 8:20 AM
$BYSI China biotech; facing regulatory risks
0 · Reply
Latest News on BYSI
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

Apr 22, 2026, 7:00 AM EDT - 3 days ago

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Files 2025 Annual Report on Form 10-K

Mar 25, 2026, 4:30 PM EDT - 4 weeks ago

BeyondSpring Files 2025 Annual Report on Form 10-K

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

Feb 9, 2026, 7:15 AM EST - 2 months ago

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

Dec 12, 2025, 7:00 AM EST - 4 months ago

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

Jul 7, 2025, 7:00 AM EDT - 10 months ago

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

Jun 3, 2025, 7:00 AM EDT - 11 months ago

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 4:30 PM EDT - 1 year ago

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

BeyondSpring Files 2024 Annual Report on Form 10-K

Mar 27, 2025, 7:05 AM EDT - 1 year ago

BeyondSpring Files 2024 Annual Report on Form 10-K

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

Jan 28, 2025, 7:00 AM EST - 1 year ago

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

Jan 28, 2025, 7:00 AM EST - 1 year ago

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

Nov 11, 2024, 8:00 AM EST - 1 year ago

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume

Oct 2, 2024, 4:11 PM EDT - 1 year ago

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

Sep 3, 2024, 7:00 AM EDT - 1 year ago

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

Aug 6, 2024, 7:00 AM EDT - 1 year ago

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

May 16, 2024, 8:00 AM EDT - 2 years ago

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring Transcript: R&D Day 2024

May 15, 2024, 10:00 AM EDT - 2 years ago

BeyondSpring Transcript: R&D Day 2024

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

May 3, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring Files 2023 Annual Report on Form 20-F

Apr 29, 2024, 5:30 PM EDT - 2 years ago

BeyondSpring Files 2023 Annual Report on Form 20-F

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

Apr 29, 2024, 5:30 PM EDT - 2 years ago

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Mar 25, 2024, 7:00 AM EDT - 2 years ago

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

Jan 10, 2024, 3:00 PM EST - 2 years ago

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Dec 18, 2023, 4:30 PM EST - 2 years ago

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BeyondSpring Transcript: Conference

Nov 7, 2023, 8:30 AM EST - 2 years ago

BeyondSpring Transcript: Conference

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor

Nov 7, 2023, 7:00 AM EST - 2 years ago

BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitor

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

Oct 23, 2023, 7:45 AM EDT - 2 years ago

SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting

Sep 27, 2023, 10:00 AM EDT - 2 years ago

BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual Meeting

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare Conference

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

May 18, 2023, 8:30 AM EDT - 3 years ago

BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting

BeyondSpring Files 2022 Annual Report on Form 20-F

Apr 18, 2023, 4:30 PM EDT - 3 years ago

BeyondSpring Files 2022 Annual Report on Form 20-F

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

Apr 18, 2023, 4:30 PM EDT - 3 years ago

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

Jan 9, 2023, 4:30 PM EST - 3 years ago

BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

Dec 13, 2022, 8:00 AM EST - 3 years ago

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

Sep 13, 2022, 7:00 AM EDT - 3 years ago

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

Aug 29, 2022, 7:00 AM EDT - 3 years ago

BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

May 27, 2022, 7:00 AM EDT - 4 years ago

BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting

BeyondSpring Files 2021 Annual Report on Form 20-F

Apr 14, 2022, 9:04 AM EDT - 4 years ago

BeyondSpring Files 2021 Annual Report on Form 20-F

BeyondSpring Earnings Call Transcript: Q4 2021

Apr 14, 2022, 8:00 AM EDT - 4 years ago

BeyondSpring Earnings Call Transcript: Q4 2021

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

Apr 14, 2022, 7:00 AM EDT - 4 years ago

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

Apr 8, 2022, 8:00 AM EDT - 4 years ago

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

BeyondSpring Cuts On-Third Of Its Workforce

Jan 12, 2022, 5:43 AM EST - 4 years ago

BeyondSpring Cuts On-Third Of Its Workforce

BeyondSpring Announces Organizational Streamlining

Jan 11, 2022, 4:05 PM EST - 4 years ago

BeyondSpring Announces Organizational Streamlining

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Dec 30, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

Dec 15, 2021, 10:23 AM EST - 4 years ago

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

Dec 15, 2021, 7:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Dec 10, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Why BeyondSpring Shares Are Diving Today

Dec 1, 2021, 3:35 PM EST - 4 years ago

Why BeyondSpring Shares Are Diving Today

BeyondSpring Shares Crater After FDA Rejects Plinabulin Application

Dec 1, 2021, 11:06 AM EST - 4 years ago

BeyondSpring Shares Crater After FDA Rejects Plinabulin Application

BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says

Dec 1, 2021, 8:13 AM EST - 4 years ago

BeyondSpring's NDA for CIN treatment 'cannot be approved' in current form, FDA says

BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

Nov 24, 2021, 8:00 AM EST - 4 years ago

BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

BeyondSpring Transcript: Study Update

Sep 20, 2021, 10:00 AM EDT - 4 years ago

BeyondSpring Transcript: Study Update

BeyondSpring Earnings Call Transcript: Q2 2021

Sep 10, 2021, 8:00 AM EDT - 5 years ago

BeyondSpring Earnings Call Transcript: Q2 2021

BeyondSpring Transcript: Conference

Aug 4, 2021, 8:30 AM EDT - 5 years ago

BeyondSpring Transcript: Conference

BeyondSpring Transcript: R&D Day 2021

Jun 25, 2021, 8:00 AM EDT - 5 years ago

BeyondSpring Transcript: R&D Day 2021

BeyondSpring Earnings Call Transcript: Q1 2021

Jun 16, 2021, 8:30 AM EDT - 5 years ago

BeyondSpring Earnings Call Transcript: Q1 2021

SuperGreenToday
SuperGreenToday Apr. 23 at 7:05 AM
$BYSI Share Price: $1.63 Contract Selected: Oct 16, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.06 – $0.08 Potential Upside: 56% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
winners3628
winners3628 Apr. 22 at 1:11 PM
$BYSI more data at asco
0 · Reply
michele1twits
michele1twits Apr. 22 at 11:34 AM
$BYSI https://ca.finance.yahoo.com/news/beyondspring-reports-compelling-data-plinabulin-110000913.html
0 · Reply
winners3628
winners3628 Apr. 10 at 12:25 PM
$BYSI https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline
0 · Reply
Goodstockday
Goodstockday Apr. 7 at 1:13 AM
$BYSI So is this a Chinese stock with an office in the US? Anyone know the history or structure?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 23 at 4:37 PM
$BYSI RSI: 56.69, MACD: 0.0538 Vol: 0.15, MA20: 1.53, MA50: 1.53 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ApolloAlerts
ApolloAlerts Mar. 20 at 3:45 PM
$BYSI 2-3$
0 · Reply
michele1twits
michele1twits Mar. 3 at 6:00 PM
$BYSI daytradersplaying silly buggers
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 4:20 PM
$BYSI RSI: 25.00, MACD: -0.1042 Vol: 0.12, MA20: 1.49, MA50: 1.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
snipethad
snipethad Feb. 17 at 8:20 AM
$BYSI China biotech; facing regulatory risks
0 · Reply
EntryTracker
EntryTracker Feb. 10 at 2:56 PM
$BYSI is a biotech (BeyondSpring) focused on oncology; has faced regulatory setbacks.
1 · Reply
Paper_Route_Frank
Paper_Route_Frank Jan. 29 at 4:30 PM
$BYSI this month looks like the bottom is in…1500 avg 2.22
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 8:20 PM
$BYSI RSI: 51.72, MACD: -0.0649 Vol: 0.10, MA20: 1.65, MA50: 1.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
michele1twits
michele1twits Jan. 21 at 2:36 PM
$BYSI
0 · Reply
Paper_Route_Frank
Paper_Route_Frank Jan. 17 at 1:20 PM
$BYSI avg 2.22
0 · Reply
winners18
winners18 Jan. 12 at 7:50 PM
$BYSI New website! will be a rewarding yr?
2 · Reply
Zeeb84
Zeeb84 Jan. 1 at 12:20 PM
$BYSI really confounded by this ticker. 500,000 shares at 2.20 is an obvious fabricated wall since that is about 5-8x daily trading volume.
3 · Reply
Zeeb84
Zeeb84 Dec. 30 at 12:59 PM
$BYSI teally really odd that at 8 AM only 5 shares traded
0 · Reply
Scan8
Scan8 Dec. 29 at 11:07 PM
$BYSI Plinabulin… It will heal much, much more thank just cancer.. It will heal everything.. It’s our time… To turn the tide..
0 · Reply
Scan8
Scan8 Dec. 29 at 10:50 PM
$BYSI ‘Anti- Parasitic’ Many human illnesses are misdiagnosed… Parasites 🦠 are the true problem.. Everything’s a lie in the matrix of lies.. Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents 2024, Bioorganic Chemistry Magdalena Podolak, ... Anna Bielawska 3.1 Candidates in current clinical trials Compounds classified to the clinical trials confirmed good anticancer properties of this group. Plinabulin (BPI-2358, Fig. 17) which is in the third phase of clinical trials has proven antitumor activity [119,120] through the colchicine-site microtubule-destabilizing effect [121]. From the chemical point of view, Plinabulin is a synthetic derivative of the natural product phenylahistin which is isolated from Aspergillus species [122]. Furthermore, a combination of plinabulin and docetaxel cause reduced side effects such as neutropenia, which are induced during the docetaxel monotherapy treatment [123].
0 · Reply